Nida Khan in TCS Nashik case: Designation disputed, pregnancy cited for bail, police deploy four teams in ongoing manhunt
Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline. byPallavi MadhirajuJuly 11, 2025